[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554804":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":45,"collaborators":47,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"episodic migraine",null,"Patients with episodic migraine will be asked to treat four spontaneous migraine attacks with sumatriptan 50 milligrams. They will register the headache characteristics and whether or not the treatment was effective.",[13],"Drug: Sumatriptan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Sumatriptan","Register the response to treatment and headache characteristics.",[9],[21],{"name":22,"affiliation":23,"role":24},"Marta Torres-Ferrús, PhD","Hospital Universitari Vall d'Hebron, Headache & Neurological Pain Research Group","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","(+34)934893000","2479","cefalea@vhir.org",[32],{"facility":33,"status":34,"city":35,"state":10,"zip":10,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hospital Universitari Vall d'Hebron","RECRUITING","Barcelona","Spain",{"type":38,"coordinates":39},"Point",[40,41],2.15899,41.38879,{"lat":41,"lon":40},[44],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48],{"name":49,"class":50},"Instituto de Salud Carlos III","OTHER_GOV","100554804",false,"NCT06503848","Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I","Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I","MAMBO","Inclusion Criteria:\n\n* Migraine with or without aura diagnosis according to ICHD-3 criteria\n* \\\u003C8 migraine days per month\n* Be able to read, write and understand instructions.\n* Have internet access and mail address\n* Signing of the informed consent\n\nExclusion Criteria:\n\n* Active preventive treatment for migraine\n* Active medication with an effect over the central nervous system\n* Serious physical or psychiatric condition\n* Cardiovascular or hepatic disease\n* Pregnant or breastfeeding women\n* Any triptan contraindication\n* Severe migraine attacks without previous response to triptans or NSAIDs","ALL","18 Years","45 Years",{"count":62,"type":63},108,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan.\n\nParticipants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.",[67],"Migraine Disorders",[69,70],"migraine","triptan","2024-10-24",{"date":73,"type":74},"2024-10-28","ACTUAL",{"date":76,"type":74},"2024-01-25",{"date":78,"type":63},"2024-12",{"name":5,"class":6},1]